Serum CD80 Emerges as Predictive Biomarker for Neoadjuvant Immunotherapy Response in Esophageal Cancer
核心洞察
Researchers identified serum CD80 (搜索) as a predictive biomarker for neoadjuvant PD-1 (搜索) blockade combined with chemotherapy in esophageal cancer (搜索) patients, with validation across two independent cohorts totaling 74 patients.
Patients with high baseline serum CD80 (搜索) levels demonstrated significantly better radiological response rates and improved progression-free survival compared to those with low CD80 levels.
CD80 (搜索)-high patients showed increased CD8 (搜索) T cell infiltration and decreased neutrophils at baseline, while CD80-low patients exhibited elevated PD-L1 (搜索) expression and immunosuppressive factors post-treatment.
A comprehensive biomarker study has identified serum CD80 (搜索) as a promising predictive marker for treatment response in esophageal cancer (搜索) patients receiving neoadjuvant PD-1 (搜索) blockade combined with chemotherapy. The research, conducted across two independent cohorts totaling 74 patients, addresses a critical clinical need as nearly 50% of esophageal cancer patients remain resistant to current neoadjuvant immunotherapy combinations.
Clinical Study Design and Patient Population
The translational analysis examined patients from a phase II clinical trial conducted between November 2019 and December 2021 at the Chinese PLA General Hospital (搜索). The study comprised a discovery cohort of 46 patients and a validation cohort of 28 patients, all diagnosed with esophageal cancer (搜索) and treated with the same neoadjuvant protocol.
The treatment regimen consisted of two cycles administered over three-week intervals, including intravenous nanoparticle albumin-bound paclitaxel (260 mg/m²), oral Tiggio capsule (S-1) taken daily from days 1-14, and intravenous Teriprizumab (搜索) (240 mg) on day 4 of each cycle. Surgery was performed within four weeks of completing neoadjuvant therapy.
Biomarker Discovery and Validation
Researchers analyzed 55 biological features from baseline blood samples, including 38 soluble immune checkpoint proteins, complete blood count parameters, metabolic indicators, and tumor biomarkers. Among all tested markers, CD80 (搜索) emerged as the most significant predictor of radiological response.
In the discovery cohort, patients with high baseline serum CD80 (搜索) levels demonstrated significantly better response rates compared to those with low levels. The predictive performance was confirmed through receiver operating characteristic analysis, yielding an area under the curve of 0.686. More importantly, CD80-high patients showed significantly longer progression-free survival and overall survival.
The validation cohort confirmed these findings, with CD80 (搜索)-high patients achieving improved response rates and an enhanced area under the curve of 0.778, strengthening the biomarker's clinical utility.
Clinical Outcomes and Treatment Efficacy
Across all 74 enrolled patients, the objective response rate reached 62.16%, with no complete responses, 62.16% partial responses, 33.78% stable disease, and 4.05% progressive disease. Among the 47 patients who underwent surgical resection, 13 patients (27.66%) achieved pathological complete response, while 24 patients (51.06%) experienced major pathological response, defined as ≤10% viable tumor remaining within the primary tumor bed.
The estimated six-month and twelve-month overall survival rates were 97.3% and 71.62%, respectively, while progression-free survival rates were 87.84% and 63.51% at the same time points.
Mechanistic Insights and Tumor Microenvironment Analysis
To understand the biological basis of CD80 (搜索)'s predictive value, researchers analyzed pre- and post-treatment transcriptome sequencing data from 23 patients in the discovery cohort. The analysis revealed distinct immune profiles between CD80-high and CD80-low patients.
At baseline, CD80 (搜索)-high patients demonstrated significantly higher CD8 (搜索) T cell infiltration and lower neutrophil counts compared to CD80-low patients. This immune profile may explain their superior response to PD-1 (搜索) blockade therapy, as CD8 T cells are crucial effector cells in anti-tumor immunity.
Post-treatment analysis revealed concerning changes in CD80 (搜索)-low patients, including significantly increased induced regulatory T cells, elevated PD-L1 (搜索) expression levels, and decreased MHC Class I signature scores. These immunosuppressive factors likely contribute to treatment resistance by creating an environment that inhibits effective T cell activation and antigen presentation.
Molecular Pathway Analysis
Gene expression analysis identified 199 up-regulated and 123 down-regulated genes in CD80 (搜索)-high patients, with these differentially expressed genes primarily associated with immune signaling pathways. The study revealed that neoadjuvant treatment modulated both metabolic and immune pathways in the tumor microenvironment.
Notably, CD80 (搜索)-low patients showed dysregulation of immunosuppressive pathways, including tryptophan metabolism and Wnt signaling. In the Wnt pathway, seven genes were significantly increased post-treatment, while three genes that negatively regulate this pathway were decreased, potentially contributing to treatment resistance.
Clinical Implications and Advantages
CD80 (搜索), also known as B7-1, is primarily expressed on antigen-presenting cells and provides co-stimulatory signals for T lymphocyte activation through CD80-CD28 (搜索) interaction. Importantly, soluble CD80 can neutralize immunosuppression mediated by PD-1 (搜索)-PD-L1 (搜索) interaction and may be more effective than PD-L1 or PD-1 antibodies in maintaining interferon-γ production by activated T lymphocytes.
The serum-based nature of this biomarker offers significant advantages over tissue-based markers, including improved accessibility, reproducibility, and the ability to avoid intratumor heterogeneity issues. This non-invasive approach could facilitate broader clinical implementation and repeated monitoring throughout treatment.
Study Limitations and Future Directions
The researchers acknowledged several limitations, including relatively small sample sizes in both cohorts and a short follow-up period in the validation cohort. The correlation between CD80 (搜索) levels and long-term survival outcomes in the validation cohort requires further analysis with extended follow-up.
Despite these limitations, the consistent findings across two independent cohorts support CD80 (搜索)'s potential as a predictive biomarker for esophageal cancer (搜索) patients receiving neoadjuvant PD-1 (搜索) blockade combined with chemotherapy. The results warrant validation in larger, more diverse patient populations to establish clinical utility and guide personalized treatment decisions.